“ADA 2026 GLP-1 Pipeline: Retatrutide, CagriSema, Orforglipron The Next Wave of Incretin Therapies Unveiled in New Orleans”. 2026. Diabzen 4 (23): 46-47. https://thediabzen.com/index.php/d/article/view/66.